Elevance Health (ELV) Earnings Analysis
Elevance Health (ELV) next reports earnings on 2026-10-20, consensus EPS 4.79 USD. Last quarter (2026-07-15) it beat with EPS 7.45 USD vs 6.21 USD est (+20%). It has beaten estimates in 5/7 recent quarters (71%). Trailing P/E 17.29.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ELV next report earnings?
| Next earnings date | 2026-10-20 |
|---|---|
| Consensus EPS estimate | 4.79 USD |
| Revenue estimate | 49.26B |
ELV earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-07-15 | 7.45 USD | 6.21 USD | +20% | Beat |
| 2026-04-22 | 12.58 USD | 10.82 USD | +16.3% | Beat |
| 2026-01-28 | 3.33 USD | 3.1 USD | +7.4% | Beat |
| 2025-10-21 | 6.03 USD | 4.93 USD | +22.3% | Beat |
| 2025-07-17 | 8.84 USD | 8.91 USD | -0.8% | Miss |
| 2025-01-23 | 3.84 USD | 3.8 USD | +1.1% | Beat |
| 2024-10-17 | 8.37 USD | 9.66 USD | -13.4% | Miss |
Beat rate: 5/7 (71%) over reported quarters with consensus data.
ELV valuation and analyst view
| Trailing P/E | 17.29 |
|---|---|
| Trailing EPS | 22.777 USD |
| Price / book | 1.89 |
| Dividend yield | 1.76% |
| Market cap | 84.11B |
| Analyst consensus | Buy (27 buy / 11 hold / 0 sell) |
| Avg price target | 444.29 USD |
Related research pages
Frequently asked questions
When is Elevance Health (ELV)'s next earnings date?
Elevance Health is next scheduled to report on 2026-10-20, with a consensus EPS estimate of 4.79 USD and revenue estimate of 49.26B.
Did ELV beat earnings last quarter?
In its 2026-07-15 report, ELV posted EPS of 7.45 USD versus a 6.21 USD estimate — a beat of 20%.
What is ELV's earnings track record?
Over the last 7 reported quarters with consensus data, ELV beat estimates 5 times (71%).
What is ELV's current P/E ratio and EPS?
ELV trades at a trailing P/E of 17.29 on trailing EPS of 22.776502983019732 USD.
What do analysts rate ELV?
Analyst consensus is "Buy" across 38 ratings (0 strong buy, 27 buy, 11 hold, 0 sell, 0 strong sell). Average 12-month price target: 444.29 USD.